{"nctId":"NCT00381680","briefTitle":"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia","startDateStruct":{"date":"2007-03"},"conditions":["B-cell Childhood Acute Lymphoblastic Leukemia","L1 Childhood Acute Lymphoblastic Leukemia","L2 Childhood Acute Lymphoblastic Leukemia","Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia"],"count":275,"armGroups":[{"label":"Regimen A: Standard vincristine dosing","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: vincristine sulfate","Drug: prednisone","Drug: doxorubicin hydrochloride","Drug: pegaspargase","Drug: cytarabine","Drug: methotrexate","Drug: dexamethasone","Drug: etoposide","Drug: cyclophosphamide","Drug: leucovorin calcium","Biological: filgrastim","Drug: asparaginase","Drug: mercaptopurine"]},{"label":"Arm B: Randomized High Dose Vincristine regimen","type":"EXPERIMENTAL","interventionNames":["Drug: vincristine sulfate","Drug: prednisone","Drug: doxorubicin hydrochloride","Drug: pegaspargase","Drug: cytarabine","Drug: methotrexate","Drug: dexamethasone","Drug: etoposide","Drug: cyclophosphamide","Drug: leucovorin calcium","Biological: filgrastim","Drug: asparaginase","Drug: mercaptopurine"]}],"interventions":[{"name":"vincristine sulfate","otherNames":["leurocristine sulfate","VCR","Vincasar PFS"]},{"name":"prednisone","otherNames":["DeCortin","Deltra"]},{"name":"doxorubicin hydrochloride","otherNames":["ADM","ADR","Adria","Adriamycin PFS","Adriamycin RDF"]},{"name":"pegaspargase","otherNames":["L-asparaginase with polyethylene glycol","Oncaspar","PEG-ASP","PEG-L-asparaginase"]},{"name":"cytarabine","otherNames":["ARA-C","arabinofuranosylcytosine","arabinosylcytosine","Cytosar-U","cytosine arabinoside"]},{"name":"methotrexate","otherNames":["amethopterin","Folex","methylaminopterin","Mexate","MTX"]},{"name":"dexamethasone","otherNames":["Aeroseb-Dex","Decaderm","Decadron","DM","DXM"]},{"name":"etoposide","otherNames":["EPEG","VP-16","VP-16-213"]},{"name":"cyclophosphamide","otherNames":["CPM","CTX","Cytoxan","Endoxan","Endoxana"]},{"name":"leucovorin calcium","otherNames":["CF","CFR","LV"]},{"name":"filgrastim","otherNames":["G-CSF","Neupogen"]},{"name":"asparaginase","otherNames":["ASNase","Colaspase","Crasnitin","Elspar","L-ASP"]},{"name":"mercaptopurine","otherNames":["6-mercaptopurine","6-MP","Leukerin","MP"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of acute lymphoblastic leukemia (ALL)\n\n  * Bone marrow with \\> 25% L1 or L2 lymphoblasts (M3 marrow)\n\n    * Patients with \\> 25% L3 marrow lymphoblasts and/or evidence of c-myc translocation are not eligible (considered Burkitt's or mature B-cell leukemia)\n* Intermediate-risk relapsed disease, meeting 1 of the following criteria:\n\n  * Bone marrow relapse ≥ 36 months after initial diagnosis (defined as M3 marrow after previous remission from ALL)\n  * Combined bone marrow and extramedullary (CNS\\* and/or testicular\\*\\*) relapse ≥ 36 months after initial diagnosis\n  * Isolated extramedullary (CNS\\* and/or testicular\\*\\*) relapse \\< 18 months after initial diagnosis\n* The following subtypes are not allowed:\n\n  * T-lineage ALL\n  * Mature B-cell (Burkitt's) leukemia (defined as L3 morphology and/or evidence of c-myc translocation)\n  * Philadelphia-chromosome positive disease\n* No Down syndrome (trisomy 21)\n* Shortening fraction \\>= 27% by echocardiogram OR ejection fraction \\>= 50% by radionuclide angiogram\n* Bilirubin \\< 3.0 mg/dL\n* Not pregnant\n* Fertile patients must use effective contraception\n* No history of peripheral neuropathy \\>= grade 3 within the past month\n* No toxicity (i.e. peripheral neuropathy) \\>= grade 3 attributable to vincristine within the past month\n* At least 5 days since prior intrathecal chemotherapy\n* No prior hematopoietic stem cell or marrow transplantation\n* No prior cranial radiotherapy \\> 1200 cGy (for patients with CNS relapse)\n* No concurrent stem cell transplant\n* No concurrent alternative therapy\n* No concurrent itraconazole in patients receiving vincristine\n* No concurrent intensity-modulated radiotherapy","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Year","maximumAge":"29 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Event Free Survival. EFS","description":"Percentage of patients who were event free at 3 years among those on Standard VCR dosing who did not undergo Hematopoietic Stem Cell Transplant (SCT).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Frequency and Severity of Adverse Effects","description":"Percentage of patients who developed at least 1 episode of grade 2 to 4 neuropathy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Gene Expression Profile","description":"Percent of unfavorable gene expression profile of early versus late marrow relapse.","classes":[]},{"type":"SECONDARY","title":"Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 1","description":"Percentage of patients who had minimal residual disease (MRD) \\< 0.01% among those with isolated BM or combined BM relapse \\>= 36 months and had successful MRD determinations at End Block 1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.8","spread":null},{"groupId":"OG001","value":"41.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 3","description":"Percentage of patients who had minimal residual disease (MRD) \\< 0.01% among those with isolated BM or combined BM relapse \\>= 36 months and had successful MRD determinations at End Block 3.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.4","spread":null},{"groupId":"OG001","value":"88.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Event Free Survival (EFS)","description":"Percentage of patients who were event free at 3 years among those with isolated BM or combined BM relapse \\>= 36 months.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.5","spread":null},{"groupId":"OG001","value":"77.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.0","spread":null},{"groupId":"OG001","value":"46.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.8","spread":null},{"groupId":"OG001","value":"83.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.5","spread":null},{"groupId":"OG001","value":"33.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Event Free Survival","description":"Adjusted percentage of patients who were event free at 3 years. For patients who received matched donor SCT, EFS was adjusted to start from the actual SCT date. For patients who did not undergo SCT, EFS was adjusted to start from median time to SCT based on patients who received matched related SCT (where patients who had events prior to SCT date were excluded from the calculation of median time to SCT).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":40,"n":203},"commonTop":["Febrile neutropenia","Neutrophil count decreased","Infections and infestations - Other, specify","Platelet count decreased","Alanine aminotransferase increased"]}}}